{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:06Z","timestamp":1786119366346,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/spc.0b013e32832ea6ae","type":"journal-article","created":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T14:53:26Z","timestamp":1250175206000},"page":"207-212","source":"Crossref","is-referenced-by-count":27,"title":["Advances in the treatment of neutropenia"],"prefix":"10.1097","volume":"3","author":[{"given":"David C","family":"Dale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210126","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice","volume":"6","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-11-20210126","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","article-title":"Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Society","volume":"144","author":"Pettengell","year":"2009","journal-title":"Br J Haematol"},{"key":"R4-11-20210126","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/COC.0b013e318165c01d","article-title":"Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model","volume":"31","author":"Dranitsaris","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"R5-11-20210126","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/pbc.21726","article-title":"Risk prediction of fever in neutropenia in children with cancer: a step towards individually tailored supportive therapy?","volume":"51","author":"Wicki","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R6-11-20210126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/00365540701670436","article-title":"Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome","volume":"40","author":"Stabell","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"R7-11-20210126","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0924-8579(08)70012-8","article-title":"Risk factors for invasive fungal infections in haematopoietic stem cell transplantation","volume":"32","author":"Camps","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"R8-11-20210126","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2165\/00003495-200868140-00002","article-title":"Patients at high risk of invasive fungal infections: when and how to treat","volume":"68","author":"R\u00fcping","year":"2008","journal-title":"Drugs"},{"key":"R9-11-20210126","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1086\/592255","article-title":"Factors associated with overall and attributable mortality in invasive aspergillosis","volume":"47","author":"Nivolx","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R10-11-20210126","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.amjmed.2008.03.034","article-title":"Clinical significance and predictors of community-onset Pseudomonas aeroginosa bacteremia","volume":"121","author":"Cheong","year":"2008","journal-title":"Am J Med"},{"key":"R11-11-20210126","first-page":"199","article-title":"Outpatient management of febrile neutropenia: time to revise the present treatment strategy","volume":"6","author":"Carstensen","year":"2008","journal-title":"J Support Oncol"},{"key":"R12-11-20210126","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00520-007-0308-x","article-title":"Clinical practice patterns of managing low-risk adult febrile neutropenia during cancer chemotherapy in the USA","volume":"16","author":"Freifeld","year":"2008","journal-title":"Support Care Cancer"},{"key":"R13-11-20210126","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.critrevonc.2007.12.003","article-title":"Palliative chemotherapy in elderly patients with common metastatic malignancies: a Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors","volume":"66","author":"Pentheroudakis","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"R14-11-20210126","doi-asserted-by":"crossref","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","article-title":"Impact of chemotherapy dose intensity of cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J Natl Compre Cancer Netw"},{"key":"R15-11-20210126","first-page":"19","article-title":"Impact of neutropenia on delivering planned chemotherapy for solid tumours","volume":"17","author":"Khan","year":"2008","journal-title":"Eur J Cancer Care"},{"key":"R16-11-20210126","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00520-007-0270-7","article-title":"Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the functional Assessment of Cancer Therapy-Neutropenia (FACT-N)","volume":"16","author":"Wagner","year":"2008","journal-title":"Support Care Cancer"},{"key":"R17-11-20210126","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdn107","article-title":"Hematopoietic growth factors: ESMO recommendations for the applications","volume":"19","author":"Greil","year":"2008","journal-title":"Ann Oncol"},{"key":"R18-11-20210126","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3747\/co.2008.198","article-title":"Canadian supportive care recommendations for the management of neutropenia in patients with cancer","volume":"15","author":"Kouroukis","year":"2008","journal-title":"Curr Oncol"},{"key":"R19-11-20210126","doi-asserted-by":"crossref","first-page":"188","DOI":"10.6004\/jnccn.2007.0019","article-title":"Myeloid growth factors: clinical practice guidelines in oncology","volume":"5","author":"Crawford","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"R20-11-20210126","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"R22-11-20210126","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejon.2007.10.001","article-title":"Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: implications for oncology nurses","volume":"12","author":"Kearney","year":"2008","journal-title":"Eur J Oncol Nurs"},{"key":"R23-11-20210126","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1524-4733.2008.00434.x","article-title":"Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy","volume":"12","author":"Ramsey","year":"2009","journal-title":"Value Health"},{"key":"R24-11-20210126","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1524-4733.2007.00242.x","article-title":"Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy","volume":"11","author":"Eldar-Lissal","year":"2008","journal-title":"Value Health"},{"key":"R25-11-20210126","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1200\/JCO.2007.13.0898","article-title":"Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy","volume":"26","author":"Timmer-Bonte","year":"2008","journal-title":"J Clin Oncol"},{"key":"R26-11-20210126","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00019053-200725040-00006","article-title":"Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective","volume":"25","author":"Cosler","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"R27-11-20210126","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.9524","article-title":"Acute myeloid leukemia or myelodysplastic syndrome (AML\/MDS) and overall mortality with chemotherapy (CT) and granulocyte colony-stimulating factor (G-CSF): a metastatic-analysis of randomized controlled trials (RCTs)","volume":"27","author":"Lyman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R28-11-20210126","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00520-008-0562-6","article-title":"Quality management of potential chemotherapy-induced neutropenia complications: evaluation of practice in an academic medical center","volume":"17","author":"Abernethy","year":"2009","journal-title":"Support Care Cancer"},{"key":"R29-11-20210126","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00277-007-0390-7","article-title":"Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes","volume":"87","author":"Zuckerman","year":"2008","journal-title":"Ann Hematol"},{"key":"R30-11-20210126","doi-asserted-by":"crossref","first-page":"657","DOI":"10.7326\/0003-4819-146-9-200705010-00009","article-title":"Systematic review: agranulocytosis induced by nonchemotherapy drugs","volume":"146","author":"Andersohn","year":"2007","journal-title":"Ann Intern Med"},{"key":"R31-11-20210126","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andres","year":"2008","journal-title":"Curr Opin Hematol"},{"key":"R32-11-20210126","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s15010-007-7132-6","article-title":"Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin","volume":"36","author":"Antonini","year":"2008","journal-title":"Infection"},{"key":"R33-11-20210126","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4314\/njm.v17i1.37357","article-title":"Neutropenia and human immunodeficiency virus-1 infection: analysis of 43 cases","volume":"17","author":"Babadoko","year":"2008","journal-title":"Niger J Med"},{"key":"R34-11-20210126","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10096-008-0531-5","article-title":"Bloodstream infections among human immunodeficiency virus-infected adult patients: epidemiology and risk factors for mortality","volume":"27","author":"Ortega","year":"2008","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R35-11-20210126","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2141.2007.06897.x","article-title":"Neutrophil elastase mutations and risk of leukaemia in severe chronic neutropenia","volume":"140","author":"Rosenberg","year":"2008","journal-title":"Br J Haematol"},{"key":"R36-11-20210126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJMp0806821","article-title":"The many causes of severe congenital neutropenia","volume":"360","author":"Dale","year":"2009","journal-title":"N Engl J Med"},{"key":"R37-11-20210126","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2141.2008.07425.x","article-title":"Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia","volume":"144","author":"Zeidler","year":"2009","journal-title":"Br J Haematol"},{"key":"R38-11-20210126","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/bmt.2008.237","article-title":"Randomized Phase III study of granulocyte transfusions in neutropenic patients","volume":"42","author":"Seidel","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R39-11-20210126","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1423-0410.2007.00971.x","article-title":"Granulocyte transfusions for neutropenic patients with life-threatening infections: a single center experience in 47 patients, who received 348 transfusions","volume":"93","author":"Ofran","year":"2007","journal-title":"Vox Sang"},{"key":"R40-11-20210126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOH.0b013e32831d7953","article-title":"Granulocyte transfusion therapy: a new era?","volume":"16","author":"Dale","year":"2009","journal-title":"Curr Op Hematol"},{"key":"R41-11-20210126","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.V88.1.335.335","article-title":"The effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans","volume":"88","author":"Price Price","year":"1996","journal-title":"Blood"},{"key":"R42-11-20210126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<7::AID-AJH2>3.0.CO;2-0","article-title":"The effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers","volume":"57","author":"Dale","year":"1998","journal-title":"Am J Hematol"},{"key":"R43-11-20210126","doi-asserted-by":"crossref","first-page":"92","DOI":"10.6004\/jnccn.2009.0008","article-title":"Neutrophil biology and the next generation of myeloid growth factors","volume":"7","author":"Dale","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"R44-11-20210126","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2710.2008.00942.x","article-title":"Biosimilars: it's not as simple as cost alone","volume":"33","author":"Roger","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"R46-11-20210126","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1470-2045(08)70304-8","article-title":"New drugs in multiple myeloma: mechanisms of action and phase I\/II clinical findings","volume":"12","author":"Ocio","year":"2008","journal-title":"Lancet Oncol"},{"key":"R47-11-20210126","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"R48-11-20210126","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2141.2008.07321.x","article-title":"Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma","volume":"143","author":"Lonial","year":"2008","journal-title":"Br J Haematol"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/SPC.0b013e32832ea6ae","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:07:47Z","timestamp":1786039667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01263393-200909000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0b013e32832ea6ae","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}